Revolution Medicines (RVMD) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 10/21/2026 – Revolution Medicines had its “buy” rating reaffirmed by TD Cowen. They now have a $250.00 price target on the stock.
• 10/19/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $240.00 to $241.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Revolution Medicines is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Revolution Medicines had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $275.00 price target on the stock.
• 10/14/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $259.00 to $260.00. They now have an “outperform” rating on the stock.
• 10/8/2026 – Revolution Medicines had its “buy” rating reaffirmed by TD Cowen.
• 10/8/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $251.00 to $259.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $239.00 to $240.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Revolution Medicines is now covered by Brookline Capital Markets. They set a “buy” rating and a $318.00 price target on the stock.
• 9/24/2026 – Revolution Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $267.00 price target on the stock.
• 9/24/2026 – Revolution Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $267.00 price target on the stock.
• 9/21/2026 – Revolution Medicines had its price target raised by Bank of America Corporation from $225.00 to $265.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Revolution Medicines is now covered by Morgan Stanley. They set an “overweight” rating and a $255.00 price target on the stock.
• 9/9/2026 – Revolution Medicines had its price target raised by Stifel Nicolaus from $215.00 to $230.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by UBS Group AG from $220.00 to $265.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Revolution Medicines had its price target raised by Guggenheim from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $203.00 to $251.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $248.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Oppenheimer Holdings, Inc. from $230.00 to $260.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $320.00 price target on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by HC Wainwright from $195.00 to $280.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Wedbush from $201.00 to $225.00. They now have an “outperform” rating on the stock.
• 8/27/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $231.00 to $239.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Revolution Medicines was upgraded by TD Cowen to “strong-buy”.

Insider Activity at Revolution Medicines

In related news, insider Alan B. Sandler sold 6,309 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the sale, the insider directly owned 52,559 shares in the company, valued at $10,624,276.26. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jack Anders sold 4,053 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $807,519.72. Following the completion of the sale, the chief financial officer directly owned 119,216 shares in the company, valued at $23,752,595.84. This trade represents a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 290,991 shares of company stock worth $59,422,765 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.